BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Report Library

All Reports
Datamonitor Healthcare Oncology Disease Analysis: NHL: Diffuse Large B-Cell Lymphoma (DLBCL)

September 17, 2021

Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of non-Hodgkin’s lymphoma (NHL), which originates in the lymphatic system when B lymphocytes become enlarged and proliferate uncontrollably to form a tumor mass. DLBCL can arise de novo or as a progression or transformation from more indolent disease such as chronic lymphocytic leukemia (in which case it is also known as Richter’s transformation) or follicular lymphoma.

Aggressive lymphomas such as DLBCL are more susceptible to chemotherapy than indolent, slowly dividing lymphomas due to the rapidly dividing nature of the malignant cells. For this reason, complete cure is possible in about half of all patients. DLBCL is the most common form of NHL, accounting for 31% of adult cases in Western countries.

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered: Diffuse Large B-Cell Lymphoma (DLBCL) - NHL
Non-Hodgkin's Lymphoma (NHL)
Back to the top Back to the top